GHRH Antagonist JMR-132 Requires p21/waf1 to Suppress Lung and Colon Cancer Cell Proliferation
Background
Growth hormone-releasing hormone (GHRH) is a neuroendocrine peptide classically known for stimulating GH release from the pituitary, but it also directly stimulates cancer cell proliferation in a broad range of tumor types in vivo and in vitro. The direct, extrapituitary proliferative mechanism of GHRH in tumor tissues remained poorly characterized prior to this work. GHRH antagonists — synthetic peptides designed to block the GHRH receptor — have shown antineoplastic activity, yet the molecular pathway through which they exert growth-inhibitory effects was unknown. The tumor suppressor p21/waf1 (CDKN1A) is a cyclin-dependent kinase inhibitor that halts cell-cycle progression, and its relationship to GHRH signaling in cancer had not been established. Understanding this link is critical for identifying which tumors are most likely to respond to GHRH antagonist therapy.
Study Design
JMR-132, a GHRH antagonist, was applied to A549 human lung cancer epithelial cells at multiple doses to assess effects on cell proliferation and p21/waf1 protein expression. GHRH itself was also applied to A549 cells to determine whether it suppressed p21 expression in a dose-dependent manner. To establish causality, p21 expression was silenced using siRNA knockdown in A549 cells, and the impact on JMR-132's anti-proliferative capacity was measured. The siRNA knockdown paradigm was replicated in HT29 human colon cancer cells and non-transformed mouse osteoblasts KS483 to test generalizability across cancer and normal cell types.
Results
JMR-132 caused a significant inhibition in the rate of cell proliferation in A549 human lung cancer cells. GHRH suppressed p21/waf1 expression in A549 cells in a dose-dependent manner, while JMR-132 increased p21 levels dose-dependently — establishing a bidirectional regulatory relationship between GHRH signaling and the p21 tumor suppressor.
Loss of
p21expression viasiRNAknockdown completely abolished the anti-proliferative effects of JMR-132 in A549 cells, proving that p21 is mechanistically required, not merely correlated.
The requirement for p21 was not cell-line specific: siRNA suppression of p21 in HT29 colon cancer cells and in non-transformed mouse osteoblasts KS483 also blocked JMR-132's anti-proliferative activity. Taken together, these results define p21/waf1 as an essential downstream effector of GHRH antagonist action, and indicate that GHRH actively represses p21 as part of its pro-proliferative signaling in extrapituitary tissues.
Key Findings
- JMR-132 caused significant inhibition of A549 lung cancer cell proliferation in a dose-dependent manner.
- GHRH suppressed p21/waf1 expression dose-dependently; JMR-132 increased p21 levels dose-dependently in A549 cells.
- siRNA knockdown of p21 completely abolished JMR-132 anti-proliferative effects in A549 lung cancer cells.
- p21 dependence confirmed in HT29 colon cancer cells and non-transformed KS483 mouse osteoblasts.
- Results suggest GHRH antagonist antineoplastic activity is applicable only in cancers expressing functional p21.
Why It Matters
Tumors that express functional p21/waf1 may be selectively vulnerable to GHRH antagonist therapy — and conversely, cancers with silenced or mutated p21 are likely non-responders. This mechanistic clarity could guide patient stratification for clinical trials involving GHRH antagonists: pre-screening tumor biopsies for p21 expression status could distinguish likely responders. For researchers and clinicians exploring peptide-based oncology, the finding reframes GHRH antagonists not as broadly cytostatic agents but as compounds operating through a specific, testable molecular checkpoint. Translation to clinical protocols remains distant — all data here are cell-culture based — but the identification of a single essential mediator substantially de-risks further preclinical and eventual clinical development of this peptide drug class.
